Badr Eman, Masoud Eman, Abdou Asmaa Gaber, Eldien Marwa Serag
Assistant Professor, Department of Biochemistry, Shebein Elkom , Menoufia, Egypt .
Lecturer, Department of Biochemistry, Shebein Elkom , Menoufia, Egypt .
J Clin Diagn Res. 2016 Dec;10(12):XC01-XC04. doi: 10.7860/JCDR/2016/22796.8985. Epub 2016 Dec 1.
B-Cell Lymphoma 6 (BCL6) has an oncogenic role in tumourigenesis of various malignancies. It represses genes involved in terminal differentiation and plays complementary role with Signal Transducer and Activator of Transcription 3 (STAT3) in triple-negative breast cancer cellular function.
To evaluate the expression of BCL6 in cancer breast and determine its correlation with the clinico-pathological features including the molecular subtype of breast carcinoma.
This prospective case control study was carried out on 150 patients, divided into 100 cases of invasive duct carcinoma not otherwise specified and 50 benign breast lesions including fibroadenoma and fibrocystic disease. Fresh tissues were excised, which were then subjected to RNA extraction. The BCL6 mRNA level was assessed using real-time reverse transcription Polymerase Chain Reaction (PCR).
There was a significant higher levels of BCL6 mRNA in malignant cases compared to benign ones (p<0.001). The level of BCL6 mRNA was higher in cases showing advanced tumor stage (p<0.04), triple negative subtype and associated in situ component (p<0.001) compared to cases with an early stage, luminal or Her 2-neu positive subtypes and those lacking in situ component.
BCL6 is up-regulated in breast cancer and is associated with poor prognostic features such as advanced stage and triple negative molecular subtype. BCL6 inhibitors might be considered as targeted therapy for breast cancer.
B细胞淋巴瘤6（BCL6）在多种恶性肿瘤的发生发展中具有致癌作用。它可抑制参与终末分化的基因，并在三阴性乳腺癌细胞功能中与信号转导和转录激活因子3（STAT3）发挥互补作用。
评估BCL6在乳腺癌中的表达，并确定其与临床病理特征（包括乳腺癌分子亚型）的相关性。
本前瞻性病例对照研究共纳入150例患者，分为100例未另行特指的浸润性导管癌和50例良性乳腺病变（包括纤维腺瘤和纤维囊性疾病）。切除新鲜组织，随后进行RNA提取。使用实时逆转录聚合酶链反应（PCR）评估BCL6 mRNA水平。
与良性病例相比，恶性病例中BCL6 mRNA水平显著更高（p<0.001）。与早期、管腔型或人表皮生长因子受体2（Her 2）-neu阳性亚型以及无原位成分的病例相比，肿瘤分期较晚（p<0.04）、三阴性亚型且伴有原位成分（p<0.001）的病例中BCL6 mRNA水平更高。
BCL6在乳腺癌中上调，且与晚期和三阴性分子亚型等不良预后特征相关。BCL6抑制剂可能被视为乳腺癌的靶向治疗药物。
